Aspirin for the prophylaxis of venous thromboembolic events in orthopedic surgery patients: A comparison of the aaos and accp guidelines with review of the evidence

Annals of Pharmacotherapy

Volumn 47, Issue 1, 2013, Pages 63-74

  Stewart, David W ^a   Freshour, Jessica E ^a  

^a EAST TENNESSEE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS; AMERICAN COLLEGE OF CHEST PHYSICIANS; ARTICLE; DEEP VEIN THROMBOSIS; DISEASE MARKER; HIGH RISK PATIENT; HIP SURGERY; HUMAN; INTERMITTENT PNEUMATIC COMPRESSION DEVICE; LUNG EMBOLISM; MEDICAL RECORD REVIEW; MEDICAL SOCIETY; ORTHOPEDIC SURGERY; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ASPIRIN; EVIDENCE-BASED MEDICINE; HUMANS; ORTHOPEDIC PROCEDURES; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; SOCIETIES, MEDICAL; UNITED STATES; VENOUS THROMBOEMBOLISM;

EID: 84872967710     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R331     Document Type: Article

References (48)

1. Geerts W, Bergqvist D, Pineo G, et al. Prevention of venous thromboem- bolism. Chest 2008;133:381S- 453S.
2. Falck-Ytter Y, Francis C, Johanson N, et al. Prevention of VTE in ortho- pedic surgery patients: antithrombotic therapy and prevention of throm- bosis, 9th edition: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:e278S-e325S.
3. Khatod M, Inacio M, Bini S, Paxton E. Pulmonary embolism prophylaxis in more than 30,000 total knee arthroplasty patients: is there a best choice? J Arthroplasty 2012;27:167-172.
4. Sharrock NE, Gonzalez Della Valle A, Go G, Lyman S, Salvati EA. Po- tent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty. Clin Orthop Relat Res 2008;466:714-721.
5. Yett HS, Skillman JJ, Salzman EW. The hazards of aspirin plus heparin. N Engl J Med 1978;298:1092.
6. American Academy of Orthopaedic Surgeons. Preventing venous thrombo- embolic disease in patients undergoing elective hip and knee arthroplasty. Evidence based guidelines and evidence report. September 24, 2011. http://www.aaos.org/research/guidelines/VTE/VTE_full_guideline.pdf (ac- cessed 2012 Jun 18).
7. American Academy of Orthopaedic Surgeons, Rosemont, IL. Clinical guideline on prevention of pulmonary embolism in patients undergoing total hip or knee arthroplasty. 2007.
8. Eikelboom J, Karthikeyan G, Fagel N, Hirsh J. American Association of Orthopedic Surgeons and American College of Chest Physicians guide- lines for venous thromboembolism prevention in hip and knee arthro- plasty differ: what are the implications for clinicians and patients? Chest 2009;135:513-520.
9. Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Pre- vention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000;355: 1295-1302.
10. Hovens M, Snoep J, Tamsma J, Huisman M. Aspirin in the prevention and treatment of venous thromboembolism. J Thromb Haemost 2006;4: 1470-1475.
11. Sobieraj-Teague M, Eikelboom J, Hirsh J. How can we reduce disagree- ment among guidelines for venous thromboembolism prevention? J Thromb Haemost 2010;8:675-7.
12. Morris G, Mitchell J. Preventing venous thromboembolism in elderly pa- tients with hip fractures: studies of low-dose heparin, dipyridamole, as- pirin, and flurbiprofen. BMJ 1977;1:535-537.
13. Pini M, Spadini E, Carluccio L, et al. Dextran/aspirin versus heparin/di- hydroergotamine in preventing thrombosis after hip fractures. J Bone Joint Surg Br 1985;67:305-309.
14. Snook GA, Chrisman OD, Wilson TC. Thromboembolism after surgical treatment of hip fractures. Clin Orthop Relat Res 1981:155;21-24.
15. Salvati EA, Lachiewicz P. Thromboembolism following total hip-re- placement arthroplasty. J Bone Joint Surg Am 1976;58:921-925.
16. Harris W, Salzman E, Athanasoulis C, Waltman A, DeSanctis R. Aspirin prophylaxis of venous thromboembolism after total hip replacement. N Engl J Med 1977;297:1246-1249.
17. McKenna R, Bachmann F, Kaushal S, Galante J. Thromboembolic dis- ease in patients undergoing total knee replacement. J Bone Joint Surg Am 1976;58:928-932.
18. Salzman E, Harris W, DeSanctis R. Reduction in venous thromboem- bolism by agents affecting platelet function. N Engl J Med 1971;284: 1287-1292.
19. Channon G, Wiley A. Aspirin prophylaxis of venous thromboembolic disease following fracture of the upper femur. Can J Surg 1979;22:468-472.
20. Stamatakis J, Kakkar V, Lawrence D, Bentley P, Nairn D, Ward V. Fail- ure of aspirin to prevent postoperative deep vein thrombosis in patients undergoing total hip replacement. BMJ 1978;1:1031.
21. Dasgupta A, Lawson K, Wilson J. Evaluating equivalence and noninferi- ority trials. Am J Health-Syst Pharm 2010;67:1337-1343.
22. Geerts W, Pineo G, Heit J, et al. Prevention of venous thromboembolism. Chest 2004;126:338S- 400S.
23. Bozic K, Vail T, Pekow P, Maselli J, Lindenauer P, Auerbach A. Does as- pirin have a role in venous thromboembolism prophylaxis in total knee arthroplasty patients? J Arthroplasty 2010;25:1053-1060.
24. Glynn R, Ridker P, Goldhaber S, Buring J. Effect of low-dose aspirin on the occurence of venous thromboembolism. Ann Intern Med 2007; 147:525-533.
25. Powers PJ, Gent M, Jay RM, et al. A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. Arch Intern Med 1989; 149:771-774.
26. Monreal M, Lafoz E, Roca J, et al. Platelet count, antiplatelet therapy and pulmonary embolism-a prospective study in patients with hip surgery. Thromb Haemost 1995;73:380-385.
27. Brookenthal KR, Freedman KB, Lotke PA, Fitzgerald RH, Lonner JH. A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty. J Arthroplasty 2001;16:293-300.
28. Freedman KB, Brookenthal KR, Fitzgerald RH Jr, Williams S, Lonner JH. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. J Bone Joint Surg Am 2000;82:929-38.
29. Westrich G, Haas S, Mosca P, Peterson M. Meta-analysis of thromboem- bolic prophylaxis after total knee arthroplasty. J Bone Joint Surg Br 2000;82:795-800.
30. Brown G. Venous thromboembolism prophylaxis after major or- thopaedic surgery: a pooled analysis of randomized controlled trials. J Arthroplasty 2009;24:S77-S83.
31. Intermountain Joint Replacement Center Writing Committee. A prospec- tive comparison of warfarin to aspirin for thromboprophylaxis in total hip and total knee arthroplasty. J Arthroplasty 2012;27:1-9.e2. doi: 10.1016/j.arth.2011.03.032
32. Jameson S, Charman S, Gregg P, Reed M, van der Meulen J. The effect of aspirin and low-molecular-weight heparin on venous thromboem- bolism after hip replacement. J Bone Joint Surg Br 2011;93:1465-1470.
33. Ji H, Lee Y, Ha Y, Kim K, Koo K. Little impact of antiplatelet agents on venous thromboembolism after hip fracture surgery. J Korean Med Sci 2011;26:1625-1629.
34. Khatod M, Inacio M, Bini S, Paxton E. Pulmonary embolism prophylax- is in more than 30,000 total knee arthroplasty patients: is there a best choice? J Arthroplasty 2012;27:167-172.
35. Gelfer Y, Tavor H, Oron A, Peer A, Halperin N, Robinson D. Deep vein thrombosis prevention in joint arthroplasties: continuous enhanced circu- lation therapy vs low molecular weight heparin. J Arthroplasty 2006;21: 206-214.
36. Westrich GH, Bottner F, Windsor RE, Laskin RS, Haas SB, Sculco TP. VenaFlow plus LovEnox vs VenaFlow plus aspirin for thromboembolic disease prophylaxis in total knee arthroplasty. J Arthroplasty 2006;21: 139-143.
37. Dorr L, Gendelman V, Maheshwari A, Boutary M, Wan Z, Long W. Multimodal thromboprophylaxis for total hip and knee arthroplasty based on risk assessment. J Bone Joint Surg Am 2007;89:2648-2657.
38. Li C, Hirsh J, Sloane D, et al. Aspirin responsiveness variability after major orthopedic surgery. Thromb Res 2012;130(2):216-220. doi: 10.1016/j.thromres.2012.04.006
39. Lachiewicz P. Comparison of ACCP and AAOS guidelines for VTE pro- phylaxis after total hip and total knee arthroplasty. Orthopedics 2009;32: 74S-78S.
40. Eikelboom J. The reemergence of aspirin for the prevention of venous thromboembolism. Clin Adv Hematol Oncol 2012;10:120-121.
41. Dager W. Warfarin for venous thromboembolism prophylaxis after elec- tive hip or knee arthroplasty: exploring the evidence, guidelines, and challenges remaining. Ann Pharmacother 2012;46:79-88. doi: 10.1345/aph.1P626
42. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007;357:2482-2494.
43. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, as- pirin, or both after myocardial infarction. N Engl J Med 2002;347:969-74.
44. The Joint Commission. Specifications manual for national hospital inpa- tient quality measures discharges 04-01-11 (2Q11) through 12-31-11 (4Q11). 2011. http://www.jointcommission.org/assets/1/6/Specs_Manu- al_3.3b_PDF.zip (accessed 2012 Jun 18).
45. Fenter T, Lewis S. Pay-for-performance initiatives. J Manag Care Pharm 2008;14:S12-5.
46. Specifications manual for national hospital inpatient quality measures, ver- sion 4.1. http://www.qualitynet.org/dcs/ContentServer?c = Page&pagename = QnetPublic%2FPage%2FQnetTier4&cid=1228771525863 (accessed 2012 May 17).
47. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxa- parin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358:2765-2775.
48. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358:2776-2786.